Anders Bröijersén

Anders Bröijersén has a diverse work experience spanning several companies and roles in the medical and pharmaceutical industry. Anders is currently the Chief Medical Officer at Moberg Pharma AB since January 2023. Prior to this, they worked at InDex Pharmaceuticals AB as a CMO from May 2022 to January 2023, and as a Senior Medical Director, Clinical Development from October 2021 to May 2022.

Before joining InDex Pharmaceuticals AB, Anders Bröijersén served as the Medical Director Drug Safety at Sobi - Swedish Orphan Biovitrum AB (publ) from August 2019 to October 2021. Anders also held positions at Swedish Orphan Biovitrum AB (Sobi), including Medical Program Director, Clinical Development from March 2016 to October 2021, and Global Medical Director Genetics and Metabolism from January 2015 to March 2016.

Prior to their tenure at Sobi, Anders Bröijersén worked at Boehringer Ingelheim as Head Medical Affairs Nordics from September 2012 to January 2015, and as Nordic Therapeutic Area Director Metabolics from an unspecified date in 2010 to September 2012.

Anders started their career at MSD as a Medical Advisor from March 2007 to August 2010. Prior to this, they worked as a Physician at Karolinska Universitetssjukhuset from March 1998 to March 2007, and as a Clinical Researcher at Karolinska Institutet from June 1990 to March 2007.

Anders Bröijersén began their education in 1987 at Karolinska Institutet, where they pursued a degree in Medicine. Anders successfully completed this program in 1998, earning the degree of MD. Continuing their academic journey at the same institution, Anders undertook a Doctor of Philosophy - PhD program in Internal Medicine, starting in 1990. After six years of dedicated study, they concluded this program in 1996, achieving their PhD in the field of Internal Medicine.